This inventor holds 14 USPTO granted patents. Top assignees: New York University, Igen, Inc., Kollmorgen Corporation. Active years: 1988-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- New York, NY (US) (1990 - 2000)
- Philadelphia, PA (US) (1988 - 2016)
Company Filing History:


Years Active: 1988-2016
Title: The Innovations of Neville Robert Kallenbach
Introduction
Neville Robert Kallenbach is a prominent inventor based in Philadelphia, PA. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative compounds and compositions. With a total of 14 patents, Kallenbach's work has the potential to impact the treatment of various medical conditions.
Latest Patents
Kallenbach's latest patents include novel s-triazine compounds and pharmaceutical compositions. These compounds are designed to prevent and treat a variety of conditions in mammals, including humans, where microbial infection is either a direct cause or a related condition. Another significant patent involves dendrimeric peptides, which demonstrate antimicrobial activity. These peptides are particularly valuable due to their rapid effect and broad spectrum of action, making them effective against microbial invasion, even in cases where standard antibiotics may fail.
Career Highlights
Throughout his career, Kallenbach has worked with notable institutions such as New York University and Igen, Inc. His research and development efforts have led to advancements in pharmaceutical compositions that address critical health issues.
Collaborations
Kallenbach has collaborated with esteemed colleagues, including Peter S. Kim and Zhigang Liu. These partnerships have further enhanced the scope and impact of his research.
Conclusion
Neville Robert Kallenbach's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile